AstraZeneca Announces New Phase III Study of Vandetanib (Zactima, ZD6474) in Patients With Advanced Lung Cancer
AstraZeneca today announced the commencement of a new Phase III study of its new investigational once-daily orally administered drug, vandetanib (ZACTIMA(R), ZD6474). Study 36 will investigate the addition of vandetanib to pemetrexed (Alimta(R)) as second line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of first line anti-cancer treatment. Study 36 will be conducted across 20 countries worldwide, including 20 sites in the United States, and is expected to enroll at least 508 patients, with the first patient entering the trial in January 2007.
This entry was posted on Monday, February 26th, 2007 at 10:50 am and is filed under Research, Treatment. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.